Inhibition of etoposide elimination in the isolated perfused rat liver by Cremophor EL and Tween 80

Cancer Chemotherapy and Pharmacology

Volumn 38, Issue 1, 1996, Pages 81-87

  Ellis, Andrew G ^a   Crinis, Nicholas A ^a   Webster, Lorraine K ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

Chemosensitizers; Etoposide; Multidrug resistance

Indexed keywords

CREMOPHOR; ETOPOSIDE; MULTIDRUG RESISTANCE REVERSING AGENT; POLYSORBATE 80; SURFACTANT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BILIARY EXCRETION; BIOASSAY; CHOLESTASIS; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; HEMOLYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ISOLATED LIVER; LIVER FUNCTION; LIVER PERFUSION; MALE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; RAT; REGIONAL PERFUSION;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BILE; CHOLESTASIS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, MULTIPLE; ETOPOSIDE; GLYCEROL; HALF-LIFE; HEMOLYSIS; LIVER; MALE; ORGAN CULTURE TECHNIQUES; PERFUSION; POLYSORBATES; RATS; RATS, SPRAGUE-DAWLEY; SURFACE-ACTIVE AGENTS;

EID: 0029960921     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050451     Document Type: Article

References (36)

1. Azmin MN, Stuart JFB, Florence AT (1985) The distribution and elimination of methotrexate in mouse blood and brain after concurrent administration of polysorbate 80. Cancer Chemother Pharmacol 14:238-242
2. Bartlett NL, Lum BL, Fisher GA, Brophy NA, Ehsan MN, Halsey J, Sikic BI (1994) Phase 1 trial of doxorubicin with cyclosporine as a modulator of multidrug resistance. J Clin Oncol 12:835-842
3. Borst P, Schinkel AH, Smit JJ, Wagenaar E, Deemter L van, Smith AJ, Eijdems EWHM, Baas F, Zaman GJR (1993) Classical and novel forms of multidrug resistance and the physiological functions of P-glycoproteins in mammals. Pharmacol Ther 60:289-299
4. Bradley G, Juranka PF, Ling V (1988) Mechanism of multidrug resistance. Biochim Biophys Acta 948:87-128
5. 2 encodes P-glycoprotein expressed in the bile canalicular membranes as determined by isoform-specific antibodies. J Biol Chem 267: 18093-18099
6. Chervinsky DS, Brecher ML, Baker RM, Hoelcle MJ, Tebbi CK (1993) Reversal of C1300 murine neuroblastoma multidrug resistance by Cremophor EL, a solvent for cyclosporin A. Cancer Biother 8:67-75
7. Colombo T, Zucchetti M, D'Incalci M (1994) Cyclosporin A markedly changes the distribution of doxorubicin in mice and rats. J Pharmacol Exp Ther 269:22-27
8. Cummings J, Forrest GJ, Cunningham D, Gilchrist NL, Soukop M (1986) Influence of polysorbate 80 (Tween 80) and etoposide (VP-16 213) on the pharmacokinetics and urinary excretion of Adriamycin and its metabolites in cancer patients. Cancer Chemother Pharmacol 17:80-84
9. De Oliveira AG, Chaimovich H (1993) Effect of detergents and other amphiphiles on the stability of pharmaceutical drugs. J Pharm Pharmacol 45:850-861
10. Friche E, Jensen PB, Sehested M, Demant EJF, Nissen NN (1990) The solvents Cremophor EL and Tween 80 modulate daunorubicin resistance in the multidrug resistant Ehrlich ascites tumor. Cancer Commun 2:297-303
11. Hande K, Bennett R, Hamilton R, Grote T, Branch R (1988) Metabolism and excretion of etoposide in isolated, perfused rat liver models. Cancer Res 48: 5692-5695
12. Hande KR (1992) Etoposide pharmacology. Semin Oncol 19 [Suppl 13]: 3-9
13. Harrison SD, Cusic AM, McAfee SM (1984) Tween 80 increases plasma adriamycin concentrations in mice by an apparent reduction of plasma volume. Eur J Cancer 17:387-389
14. 14C-etoposide in man. Proc Am Soc Clin Oncol 14:168
15. Keller RP, Altermatt HJ, Donaisch P, Zihlmann H, Laissue JA, Hiestand PC (1992) Pharmacologic interactions between the resistance-modifying cyclosporine SDZ PSC 833 and etoposide enhance in vivo cytostatic activity and toxicity. Int J Cancer 51:433-438
16. Kerr DJ, Graham J, Cummings J, Morrison JG, Thompson GG, Brodie MJ, Kaye SB (1986) The effect of verapamil on the pharmacokinetics of Adriamycin. Cancer Chemother Pharmacol 18:239-242
17. Kessel D (1992) Properties of Cremophor EL micelles probed by fluorescence. Photochem Photobiol 56:447-451
18. Kongshaug M, Cheng LS, Moan J, Rimington C (1991) Interaction of Cremophor EL with human plasma. Int J Biochem 23:473-478
19. Lum BL, Kaubisch S, Yahanda AM, Adler KM, Jew L, Ehsan MN, Brophy NA, Halsey J, Gosland MP, Sikic BI (1992) Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase 1 trial to modulate multidrug resistance, J Clin Oncol 10: 1635-1642
20. Millward MJ, Webster LK, Rischin D, Tinnelly CA, Toner GC, Bishop JF, Linsenmeyer ME, Woodcock DM (1994) Phase I trial of Cremophor EL and doxorubicin in patients with advanced solid tumours. Ann Oncol 5 [Suppl 2]: 159
21. Raderer M, Scheithauer W (1993) Clinical trials of agents that reverse multidrug resistance. Cancer 72:3553-3563
22. Ruetz S, Gros P (1994) Phosphatidylcholine translocase: a physiological role for the mdr2 gene. Cell 77:1071-1081
23. Schuurhuis GJ, Broxterman HJ, Pinedo HM, Heijningen HM van, Kalken CK van, Vermorken JB, Spoelstra EC, Lankelma J (1990) The polyoxyethylene castor oil Cremophor EL modifies multidrug resistance. Br J Cancer 62:591-594
24. Sinicrope FA, Dudeja PK, Bissonnette BM, Safa AR, Brasitus TA (1992) Modulation of P-glycoprotein-mediated drug transport by alterations in lipid fluidity of rat liver canalicular membrane vesicles. J Biol Chem 267:24995-25002
25. Speeg KV, Maldonado AL (1993) Effect of cyclosporine on colchicine partitioning in the rat liver. Cancer Chemother Pharmacol 32:434-436
26. Speeg KV, Maldonado AL (1994) Effect of the nonimmunosuppressive cyclosporin analog SDZ PSC-833 on colchicine and doxorubicin biliary secretion by the rat in vivo. Cancer Chemother Pharmacol 34:133-136
27. Sridhar R, Dwivedi C, Anderson J, Baker PB, Sharma HM, Desai P, Engineer FN (1992) Effects of verapamil on the acute toxicity of doxorubicin in vivo. J Natl Cancer Inst 84:1653-1660
28. Stapf V, Thalhammer T, Huber-Huber R, Felberbauer F, Gajdzik L, Graf J (1994) Inhibition of rhodamine 123 secretion by cyclosporin A as a model of P-glycoprotein mediated transport in liver. Anticancer Res 14:581-586
29. Sykes E, Woodburn K, Decker D, Kessel D (1994) Effects of Cremophor EL on distribution of Taxol to serum lipoproteins. Br J Cancer 70:401-404
30. Valk P van der, Kalken CK van, Ketelaars H, Broxterman HJ, Scheffer G, Kuiper CM, Tsuruo T, Lankelma J, Meijer CJLM, Pinedo HM, Scheper RJ (1990) Distribution of multi-drug resistance-associated P-glycoprotein in normal and neoplastic human tissues. Ann Oncol 1:56-64
31. Watanabe T, Miyauchi S, Sawada Y, Iga T, Hanano M, Inaba M, Sugiyama Y (1992) Kinetic analysis of hepatobiliary transport of vincristine in perfused rat liver: possible roles of P-glycoprotein in biliary excretion of vincristine. J Hepatol 16:77-88
32. Webster L, Linsenmeyer M, Millward M, Morton C, Bishop J, Woodcock D (1993) Measurement of Cremophor EL following Taxol: plasma levels sufficient to reverse drug exclusion mediated by the multidrug-resistance phenotype. J Natl Cancer Inst 85:1685-1690
33. Webster LK, McCormack JJ (1986) Influence of hypoxia on the metabolism and biliary excretion of trimetrexate by the isolated perfused rat liver. Biochem Pharmacol 35:4587-4589
34. Woodcock DM, Jefferson S, Linsenmeyer ME, Crowther PJ, Chojnowski GM, Williams B, Bertoncello I (1990) Reversal of the multidrug resistance phenotype with Cremophor EL, a common vehicle for water-insoluble vitamins and drugs. Cancer Res 50:4199-4203
35. Woodcock DM, Linsenmeyer ME, Chojnowski G, Kriegler AB, Nink V, Webster LK, Sawyer WH (1992) Reversal of multidrug resistance by surfactants. Br J Cancer 66:62-68
36. Yokoyama M, Miyauchi M, Yamada N, Okano T, Sakurai Y, Kataoka K, Inoue S (1990) Characterization and anticancer activity of the micelle-forming polymeric anticancer drug adriamycin-conjugated poly(ethylene glycol)-poly(aspartic acid) block copolymer. Cancer Res 50:1693-1700